Spencer Pharmaceutical (SPPH)

[read_this_n0w]

Is Dr Arella Dr Evil Or biotech entrepreneur with inherent biotech risks ?

Dr Arella is being labelled synonymous to 100% pump and dump items and his academic achievements are waved away in a wiff.

SPPH ceo dr arella and VPRO committee chairman:
" Dr. Maximilien Arella, Chairman, Scientific Advisory Committee "

Dr Arella is also involved with VPRO as stated at the the 2nd halve of this posting. And what do you know..VPRO is NOT a scam.
How on earth is that possible with the biggest madoff promotor known to man if some topics are to be believed?

"Viropro, Inc. Acquires A Major Biotech GMP Production Facility "
------------------------------------------------------
When someone would ask how VPRO diluting with shares to acquire an asset is in any way good to oldtime shareholders, this would be the answer:
(the acquisition was done at 4 cents per share, see the PR at bottom of this posting)

"In that particular example, three months high was .20 cents.. with a close of 7 cents that day after a spike in december.
BUT in past THREE years prior all shares traded mostly between two and three cent
so yes... they did a good deal, got a tangible asset to use with their IP rights
You cant have it all when a company does not have revenue yet,
they either dilute to get access to revenue
(thorugh dilution OR in this case share based purchase)
OR they turn to licensing model

i am quite fond of licensing model managements btw, lowers risk dramatically"

--------------------------------------------------------
When someone asked how is it good that VPRO diluted shares for the old holders, this would be the answer:
"Its about the acquiring of an asset, i know a company who bought 10mln similar asset from baxter which was written off , built on it for three years and sold ir for 100mln+.

Same goes for dilution, dilution never nice nor are asset stock purchases, BUT if there is value creation thats mostly less nice for old holders who often have to wait for 1-3 years for the newly acquired assets to chip in, its still building a business and not a scam.
Most biotech btw dilute since they bleed cash, little difference between that and buying an asset in an all share deal.
Both build thouhg... first with advancing trials, 2nd with new asset to build upon or utilize.
So the argument was not wether it was nice to old holders, the argument was that that comapny seems to be doing fine rebuilding itself.
"
"VPRO not too bad seeing past pricing imo.
and i would not invest due to him, but i dont mind him being around if the technology there is interesting enough.

problem remains with tiny microcaps, they are high risk, but also extremely high gain if/when they do pay off"
----------------
No opinion on SPPH but about dr Arella since he is so often the topic here:

Not all as black and white as some would like to present.
And not all doom and gloom where the man is involved, unlike the preferred interest of some. Which does NOT give a final opinion on SPPH one way or the other, there may be issues here.. BUT ....
He does seems to be involved with multiple companies. In part this is understandable.
Seems he mostly tries to broker deals between french speaking universities (where he had a good academic background himself) and commercial companies.

Fact remains that a lot of biotech programs mainlyfail due to data failing either early stage development or late stage development.

"Dr. Maximilien Arella is a Professor at the Microbiology and Biotechnology Research Centre, INRS - Institut Armand - Frappier, at the University du Qu?bec in Montreal. Dr. Arella brings with him extensive international experience in the field of molecular biology and monoclonal antibody development. Combining both an experience of researcher and entrepreneur, he is a member of various national and international committees on infectious diseases and expression of recombinant proteins.

Since 1984, Dr. Arella has been scientific advisor and counsellor for Dr. Tetsuo Nakamura, president of the ?Institute of Immunology Co. Ltd.? based in Tokyo, Japan. From 1996 to 2001, Dr. Arella was a founding member and shareholder of Sapientia Therapeutics, a Canadian biotech company, active in the evaluation of an additive boosting cellular immunity.

Since 1998, Dr. Arella has acted as president and shareholder of Perigene Inc, a company who owns platform technologies from INSA-Rouen and from the UTC-Compi?gne in France. He also acted as president and shareholder of Sannica Biotech-Pharma since 1999, whose aim is to increase the value of certain platforms coming from Japan (University of Tokyo, Kyoto and Osaka).

His academic research is mainly based in the fields of molecular biology, fundamental aspects and applications of the double-stranded RNA virus, as well as amplification systems for the analysis of human and animal viruses, and cancer markers. Since 1993, Dr. Arella carried out two mandates as chairman of the Virology Research Center of the IAF during which he held the responsibility of managing both the research and the teaching programs.

DR. Arella holds a Post-doctorate Degree in Biotechnology from the Roche Institute of Molecular Biology in New Jersey, has a Ph.D. in virology from the Institut Armand Frappier / Universit? de Rouen and obtained a Master?s Degree in Microbiology-Immunology from the Universit? de Montr?al.
"

A different example......

TYPE OF COMPANY
Public Company (OTC BB – NASDAQ : VPRO)
TEAM
? Dr. Jean-Marie Dupuy, President and CEO
? Gino Di Iorio, C.A., CFO
? Prosper Azoulay, VP Operations
? Andre Bedard, Business Development and International Partnerships
? Patrick Daoust, Director, Bio-Therapeutics
? Patrick Benoist, Project Director
? Dr. Maximilien Arella, Chairman, Scientific Advisory Committee

VPRO made a good deal there to proceed with their own
Background
http://www.viropro.com/modules/AxialRealisation/img_repository/files/documents/Corporate%20Profile.doc


Viropro, Inc. Acquires A Major Biotech GMP Production Facility

Press Release Source: VIROPRO On Tuesday February 22, 2011, 7:47 am EST IRVINE, Calif.--(BUSINESS WIRE)-- VIROPRO (Pink Sheets:VPRO.pk - News) announces it has acquired Alpha Biologics Sdn. Bhd. of Penang, Malaysia, through a Share Purchase Agreement.

Acquisition is paid through issuance of 525,000,000 shares valued at US$0.04 each, representing a total value of US$21 million. The offer and sale of the shares was made pursuant to a non-US person pursuant to Rule 903(b)(3).

Alpha Biologics is a contract process development and GMP biomanufacturing company, with process development laboratories located in the biotech cluster of Cambridge, UK and a state-of-the-art 5,000 sq. meter advanced GMP mammalian cell clinical production facility located in the Penang Science Park, Malaysia, with 30 employees. Alpha Biologics provides its clients with supplies of mammalian cell proteins, such as monoclonal antibodies or recombinant proteins, or other cell-derived products.

Over the next few months, the plant will undergo due process to obtain its certification under the Pharmaceutical Inspection Cooperation Scheme (PIC/s), which is a global harmonization scheme for Good Manufacturing Practices (GMP) with 39 member countries and agencies, including the US FDA. EMEA accreditation will follow thereafter.

Dr. Rajiv Datar, President and CEO of Viropro comments: “With this acquisition, Viropro has taken the first step towards creating a global biotech contract services business, and towards achieving our goal of offering an integrated Contract Development and GMP Manufacturing Services platform to our clients in the Biopharmaceutical industry. We anticipate further acquisitions as we make progress and are very pleased to count on the support of SpringHill Management Ltd. UK, along with that of a talented and committed team of scientists, engineers and specialists, in our endeavor.”

Dato Dr. Kim Tan, Chairman of SpringHill Management and of Alpha Biologics adds: “This transaction allows us to participate in the entire biotech Contract Development and Manufacturing services offering, and thus provides increased leverage to our Penang facility. We look forward to working closely with Viropro and its other subsidiaries towards the realization of a common mission, which is to ‘make biotech drugs for clients, efficiently and economically.’”

This acquisition will create the emergence of a new controlling shareholder, and thus a shareholders’ meeting will be held on April 28, 2011 in San Diego to seek shareholder approval.

-----------------------------------------


This is NOT an endorsement of SPPH or an advice against it, just an observation that not all is black and white.